ZyVersa Therapeutics Statistics
Share Statistics
ZyVersa Therapeutics has 3.62M
shares outstanding. The number of shares has increased by 200.42%
in one year.
| Shares Outstanding | 3.62M |
| Shares Change (YoY) | 200.42% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | n/a |
| Failed to Deliver (FTD) Shares | 2,579 |
| FTD / Avg. Volume | 0.07% |
Short Selling Information
The latest short interest is 362.27K, so 10.01% of the outstanding
shares have been sold short.
| Short Interest | 362.27K |
| Short % of Shares Out | 10.01% |
| Short % of Float | 10.02% |
| Short Ratio (days to cover) | 1 |
Valuation Ratios
| PE Ratio | 0 |
| Forward PE | -0.01 |
| PS Ratio | 0 |
| Forward PS | 0.1 |
| PB Ratio | 0 |
| P/FCF Ratio | -1.56 |
| PEG Ratio | 0 |
Financial Ratio HistoryEnterprise Valuation
Currently the Enterprise Value (EV) is not available for ZyVersa Therapeutics.
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 0.15,
with a Debt / Equity ratio of 0.
| Current Ratio | 0.15 |
| Quick Ratio | 0.15 |
| Debt / Equity | 0 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | -33858.18 |
Financial Efficiency
Return on Equity is n/a and Return on Invested Capital is n/a.
| Return on Equity | n/a |
| Return on Assets | n/a |
| Return on Invested Capital | n/a |
| Revenue Per Employee | n/a |
| Profits Per Employee | $-1,344,776,428.57 |
| Employee Count | 7 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | -6.75M |
| Effective Tax Rate | 0.07% |
Stock Price Statistics
The stock price has increased by -89.88% in the
last 52 weeks. The beta is 0.66, so ZyVersa Therapeutics's
price volatility has been higher than the market average.
| Beta | 0.66 |
| 52-Week Price Change | -89.88% |
| 50-Day Moving Average | 0.72 |
| 200-Day Moving Average | 1.58 |
| Relative Strength Index (RSI) | 38.61 |
| Average Volume (20 Days) | 3,643,461 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -9.14B |
| Net Income | -9.41B |
| EBITDA | -9.14B |
| EBIT | -9.15B |
| Earnings Per Share (EPS) | -848.03 |
Full Income StatementBalance Sheet
The company has 1.53M in cash and 0 in
debt, giving a net cash position of 1.53M.
| Cash & Cash Equivalents | 1.53M |
| Total Debt | n/a |
| Net Cash | n/a |
| Retained Earnings | -112.63B |
| Total Assets | 20.6M |
| Working Capital | -9.52M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was -7.56M
and capital expenditures 0, giving a free cash flow of -7.56M.
| Operating Cash Flow | -7.56M |
| Capital Expenditures | n/a |
| Free Cash Flow | -7.56M |
| FCF Per Share | -0.68 |
Full Cash Flow StatementMargins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
